Spectrum of PHEX Mutations and FGF23 Profiles in a Taiwanese Cohort With X-Linked Hypophosphatemia Including 102 Patients
Pen-Hua Su,Ju-Shan Yu,Yu-Zhen Wu,Yu-Shen Tsai,Fu-Sung Lo,Ju-Li Lin,Mei-Chyn Chao,Chia-Chi Hsu,Yu-Yuan Ke,Pao-Chin Chiu,Jo-Ching Chen,Ying-Hua Huang,Shuan-Pei Lin,Yen-Yin Chou,Wei-Hsin Ting,Shuo-Yu Wang,Chiao-Fan Chiu,Yen-Chun Huang,Hui-Pin Hsiao,Chao-Hsu Lin,Chung-Hsing Wang,DA-Tian Bau,Ching-Yuang Lin,PEN-HUA SU,JU-SHAN YU,YU-ZHEN WU,YU-SHEN TSAI,FU-SUNG LO,JU-LI LIN,MEI-CHYN CHAO,CHIA-CHI HSU,YU-YUAN KE,PAO-CHIN CHIU,JO-CHING CHEN,YING-HUA HUANG,SHUAN-PEI LIN,YEN-YIN CHOU,WEI-HSIN TING,SHUO-YU WANG,CHIAO-FAN CHIU,YEN-CHUN HUANG,HUI-PIN HSIAO,CHAO-HSU LIN,CHUNG-HSING WANG,DA-TIAN BAU,CHING-YUANG LIN
DOI: https://doi.org/10.21873/invivo.13444
2023-12-25
In Vivo
Abstract:BACKGROUND/AIM: X-linked hypophosphatemia (XLH), the most common form of hereditary rickets, results from loss-of-function mutations in the phosphate-regulating PHEX gene. Elevated fibroblast growth factor 23 (FGF23) contributes to hypophosphatemia in XLH. This study aimed to characterize PHEX variants and serum FGF23 profiles in Taiwanese patients with XLH.PATIENTS AND METHODS: We retrospectively reviewed the records of 102 patients clinically suspected of having hypophosphatemic rickets from 2006 to 2022. Serum intact Fibroblast growth factor-23 (iFGF23) levels were measured on clinic visit days. PHEX mutations were identified using Sanger sequencing, and negative cases were analyzed using whole-exome sequencing.RESULTS: The majority (92.1%) of patients exhibited elevated FGF23 compared with normal individuals. Among 102 patients, 44 distinct PHEX mutations were identified. Several mutations recurred in multiple unrelated Taiwanese families. We discovered a high frequency of novel PHEX mutations and identified variants associated with extreme FGF23 elevation and tumorigenesis.CONCLUSION: Our findings revealed the PHEX genotypic variants and FGF23 levels in Taiwanese patients with XLH. These results are crucial given the recent approval of burosumab, a monoclonal FGF23 antibody, for XLH therapy. This study provides key insights into the clinical management of XLH in Taiwan.
medicine, research & experimental